Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENVARSUS XR vs PIMECROLIMUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Prophylaxis of organ rejection in kidney transplant patients,Prophylaxis of organ rejection in liver transplant patients
Mild to moderate atopic dermatitis in immunocompetent patients aged 2 years and older,Off-label: psoriasis, seborrheic dermatitis, vitiligo, lupus erythematosus
0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
Terminal half-life approximately 25-30 hours in stable renal transplant patients. Longer half-life (up to 50 hours) in patients with hepatic impairment.
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Primarily hepatic via CYP3A4 and CYP3A5; also metabolized by intestinal CYP3A4.
Primarily metabolized via hepatic cytochrome P450 3A4 (CYP3A4) to O-demethylated metabolites; also undergoes further hydroxylation and glucuronidation.
Primarily fecal (94%) with minor renal excretion (2.2% as unchanged drug). Biliary excretion is a significant route.
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Approximately 99% bound to erythrocytes and plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.9-1.4 L/kg in renal transplant patients; large volume indicates extensive tissue distribution, particularly to red blood cells.
Approximately 1.3 L/kg (range 0.6–2.1 L/kg), indicating extensive tissue distribution.
Oral bioavailability is approximately 15-25% with the extended-release formulation; reduced by high-fat meal, so should be taken consistently on an empty stomach.
Topical: Systemic bioavailability is very low (<0.5% of applied dose) based on blood concentration measurements.
No specific GFR-based dose adjustment; however, due to nephrotoxicity, monitor renal function closely and reduce dose if renal impairment occurs. For patients with severe renal impairment (Cr Cl <30 m L/min), consider alternative immunosuppression.
No dose adjustment required for renal impairment; systemic absorption is minimal (<2.5%).
In patients with mild to moderate hepatic impairment (Child-Pugh A or B), reduce dose by 25%. For severe hepatic impairment (Child-Pugh C), reduce dose by 50% and monitor trough levels closely.
No formal studies in hepatic impairment; based on minimal systemic absorption, no adjustment is likely required, but use caution in severe hepatic impairment due to theoretical risk of increased exposure.
For pediatric kidney transplant recipients: 0.2 mg/kg/day orally once daily, with morning meal. Adjust to target trough concentrations. Safety and efficacy not established for other indications in pediatrics.
Children ≥2 years: Apply a thin layer of 1% cream to affected areas twice daily; maximum application area: <20% body surface area. Avoid use in children <2 years due to risk of systemic effects (insufficient data).
No specific dose adjustment; however, elderly patients may have increased susceptibility to nephrotoxicity and neurotoxicity. Use lowest effective dose, monitor renal function, and adjust based on trough levels.
No specific dose adjustment; use lowest effective amount due to potential for increased skin sensitivity and renal function decline with age.
Increased susceptibility to infection and possible development of malignancy (e.g., lymphoma, skin cancer).
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; avoid continuous long-term use; limit use to indicated short-term and intermittent treatment.
Nephrotoxicity, neurotoxicity, hypertension, hyperkalemia, post-transplant diabetes mellitus, monitoring of blood concentrations required.
Increased risk of infections (e.g., varicella zoster, herpes simplex); avoid use on active infections; possible lymphadenopathy; photosensitivity (avoid UV exposure); monitor for skin atrophy; not recommended in children <2 years; use during pregnancy only if clearly needed.
Hypersensitivity to tacrolimus or any component of the formulation.
History of hypersensitivity to pimecrolimus or any component of the formulation; Netherton syndrome; generalized erythroderma; active viral, bacterial, or fungal skin infections at application site.
Grapefruit and grapefruit juice increase tacrolimus exposure and must be avoided. High-fat meals may decrease absorption; consistency of food intake relative to dosing is recommended. Alcohol should be limited due to potential additive hepatotoxicity.
No known food interactions with topical pimecrolimus. Oral ingestion should be avoided; however, accidental small amounts on skin are unlikely to cause systemic effects.
Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on animal studies; human data are limited but suggest a possible small increase. During the second and third trimesters, risks include intrauterine growth restriction, preterm delivery, and transient neonatal hyperkalemia and renal dysfunction. Advise women of childbearing potential to use effective contraception.
Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk due to systemic absorption; avoid if possible. Second and third trimesters: limited data; risk of fetal harm cannot be excluded.
Tacrolimus is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.5 (range 0.12–0.75). Infant exposure is estimated to be <1% of the maternal weight-adjusted dose, which is considered low. However, due to potential for immunosuppression and adverse effects, breastfeeding is generally not recommended unless benefits outweigh risks. Monitor infant for signs of immunosuppression.
It is not known whether pimecrolimus is excreted in human milk. Systemic absorption after topical application is minimal (<2.5 ng/m L), suggesting negligible transfer. However, due to potential for serious adverse reactions in nursing infants, caution should be exercised. M/P ratio is not available. Breastfeeding is generally considered acceptable with cautious use.
Pregnancy induces pharmacokinetic changes including increased volume of distribution, altered protein binding, and enhanced clearance of tacrolimus. Frequent monitoring of trough concentrations is essential to maintain therapeutic levels (target 5–10 ng/m L). Dose adjustments (increases of 20–50% or more) are often required, especially during the second and third trimesters. Postpartum, doses should be reduced to pre-pregnancy levels within 1–2 weeks.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy. Use the minimum amount necessary to control symptoms, and avoid application to large body surface areas or prolonged use. Systemic absorption is minimal and unlikely to be altered significantly during pregnancy.
ENVARSUS XR is an extended-release formulation of tacrolimus; conversion from immediate-release tacrolimus requires close therapeutic drug monitoring due to altered pharmacokinetics. Administer consistently with or without food to minimize variability. Avoid grapefruit products. Monitor renal function, blood pressure, electrolytes, glucose, and trough tacrolimus levels. CYP3A4/5 inducers/inhibitors significantly affect tacrolimus exposure; adjust dose accordingly. Do not crush, chew, or split tablets.
Pimecrolimus is a topical calcineurin inhibitor used for mild-to-moderate atopic dermatitis. It is not indicated for use in children under 2 years. Avoid use on infected skin; monitor for local irritation. Long-term safety concerns include potential increased risk of lymphoma and skin malignancies; use minimal amounts for shortest duration necessary. Do not use with occlusive dressings. Consider intermittent therapy for flares.
Take exactly as prescribed, at the same time each day, with or without food but consistently.,Swallow whole; do not crush, chew, or break the tablet.,Avoid grapefruit and grapefruit juice.,Do not stop or change dose without consulting your doctor.,Report signs of infection (fever, sore throat), tremor, headache, changes in urination, or unusual bleeding.,Avoid live vaccines and limit sun exposure due to increased skin cancer risk.,Keep all appointments for blood tests to monitor drug levels and organ function.
Apply a thin layer only to affected areas, avoiding eyes, mouth, and broken skin.,Do not cover treated area with bandages or wraps unless directed by your doctor.,Wash hands after applying unless treating hands.,Avoid sun exposure, tanning beds, and UV therapy while using this medication.,Report any signs of infection, skin burning, or worsening rash.,Do not use for prolonged periods; use only until symptoms clear.,Inform your doctor if you are pregnant, breastfeeding, or have a weakened immune system.
No interactions on record
"Pimecrolimus, a calcineurin inhibitor, and panobinostat, a histone deacetylase inhibitor, both have immunosuppressive and potential myelosuppressive effects. Concurrent use may synergistically increase the risk of infections, including opportunistic infections, and hematologic toxicities such as neutropenia, thrombocytopenia, and anemia. Additionally, both drugs can prolong the QT interval, potentially increasing the risk of serious cardiac arrhythmias like torsade de pointes."
"Pimecrolimus, a calcineurin inhibitor used topically, can inhibit CYP3A4 activity to a mild degree, potentially decreasing the metabolism of nilotinib, a BCR-ABL tyrosine kinase inhibitor that is predominantly metabolized by CYP3A4. This may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, hepatotoxicity, and other dose-related adverse effects. Therefore, patients should be carefully monitored for signs of nilotinib toxicity."
"Pimecrolimus and sirolimus both suppress immune function via distinct but overlapping mechanisms. Pimecrolimus inhibits calcineurin, reducing T-cell activation, while sirolimus inhibits mTOR, blocking cytokine-driven T-cell proliferation. Concomitant use increases the risk of over-immunosuppression, leading to higher susceptibility to infections, lymphoproliferative disorders, and possibly nephrotoxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENVARSUS XR vs PIMECROLIMUS, answered by our medical review team.
ENVARSUS XR is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.. PIMECROLIMUS is a Calcineurin Inhibitor that works by Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENVARSUS XR and PIMECROLIMUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENVARSUS XR is: 0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.. The standard adult dose of PIMECROLIMUS is: Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENVARSUS XR and PIMECROLIMUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENVARSUS XR is classified as Category C. Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on anima. PIMECROLIMUS is classified as Category A/B. Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.